Alterity Therapeutics (ATHE) Capital Expenditures (2016 - 2019)

Alterity Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at -$5123.2 for Q4 2019.

• In Q4 2019, Capital Expenditures fell 118.19% year-over-year to -$5123.2; the TTM figure through Dec 2019 stood at -$26661.1 (changed N/A YoY), while the FY2024 annual figure was -$5722.0, changed N/A from the prior year.
• Capital Expenditures was -$5123.2 for Q4 2019 at Alterity Therapeutics, down from -$2348.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$2348.0 in Q4 2018 to a low of -$16622.8 in Q4 2016.
• Historically, Capital Expenditures has averaged -$6665.3 across 4 years, with a median of -$3845.1 in 2017.
• The sharpest annual moves came in 2017 and 2019: Capital Expenditures surged 84.56% in 2017, then sank 118.19% in 2019.
• A 4-year view of Capital Expenditures shows it stood at -$16622.8 in 2016, then soared by 84.56% to -$2567.1 in 2017, then gained by 8.53% to -$2348.0 in 2018, then sank by 118.19% to -$5123.2 in 2019.
• The last three Capital Expenditures figures came in at -$5123.2 (Q4 2019), -$2348.0 (Q4 2018), and -$2567.1 (Q4 2017), per Business Quant data.